<DOC>
	<DOCNO>NCT02900378</DOCNO>
	<brief_summary>The purpose randomize , actively control , double-blind study demonstrate superiority sacubitril/valsartan enalapril increase non-sedentary physical activity chronic heart failure patient reduce ejection fraction . Physical activity continuously measure mean wrist-worn accelerometry device 2 week 12 week start study therapy ( sacubitril/valsartan enalapril ) .</brief_summary>
	<brief_title>randOmized stUdy Using acceleromeTry Compare Sacubitril/valsarTan Enalapril Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Written inform consent obtain study assessment perform . Ambulatory ≥ 18 year age diagnosis chronic symptomatic HF ( NYHA class ≥ II ) reduce ejection fraction , define know LVEF ≤ 40 % AND one follow two criterion : Plasma NTproBNP level ≥ 300 pg/mL BNP ≥ 100 pg/mL ( measurement may record long past 12 month ) OR Confirmation heart failure hospitalization last 12 month . Patients must stable HF medication least 4 week prior Week 2 , minimal daily dose current evidence base therapy equivalent least 2.5 mg/d enalapril Willingness wear accelerometer wristband continuously duration trial . Patients must live setting , allow move freely primarily selfresponsible schedule sleep daily activity . History hypersensitivity study drug excipients drug similar chemical class Use sacubitril/valsartan prior week 2 . Bedridden patient , patient significantly impaired/limited physical activity and/or fatigue due medical condition HF , , limited angina ( chest pain exertion ) , arthritis , gout , peripheral artery occlusive disease , obstructive restrictive lung disease , malignant disease , neurological disorder ( e.g . Parkinson 's Alzheimer 's disease , central peripheral neuroinflammatory degenerative disorder functional central nervous lesion due hemodynamic traumatic incident ) , injury ( incl . diabetic foot ulcer ) miss limbs Patients palsy , tremor rigor affect nondominant arm . Patients skin condition nondominant arm would limit ability wear actigraphy device continuously ( 24h/day ) 14 week . Patients fully depend mobility support system , e.g . wheelchair , scooter walker . Patients allow use cane long use nondominant arm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>physical activity</keyword>
	<keyword>actigraphy</keyword>
	<keyword>sleep</keyword>
	<keyword>sacubitril/valsartan</keyword>
	<keyword>enalapril</keyword>
	<keyword>heart failure</keyword>
	<keyword>reduce ejection fraction</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>accelerometry</keyword>
</DOC>